EICHOR
● Active Not Recruiting
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Condition: Solid Tumors · Sponsor: Hoffmann-La Roche
About this study
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors will be treated with a drug or drug regimen tailored to their NGS assay results at screening. Participants will be assigned to the appropriate cohort based on their genetic alteration(s). Treatment will be assigned on the basis of relevant oncogenotype, will have cohort-specific inclusion/exclusion criteria, and, unless otherwise specified, will continue until disease progression, loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (114)
| Western Regional Medical Center at Cancer Treatment Centers of America | Goodyear, Arizona, United States | — |
| Kaiser Permanente Los Angeles | Los Angeles, California, United States | — |
| USC Norris Cancer Center | Los Angeles, California, United States | — |
| Hoag Memorial Hospital | Newport Beach, California, United States | — |
| UC Davis Comprehensive Cancer Center | Sacramento, California, United States | — |
| University Cancer & Blood Center, LLC | Athens, Georgia, United States | — |
| St. Alphonsus | Boise, Idaho, United States | — |
| Midwestern Regional Med Center | Zion, Illinois, United States | — |
| Horizon Oncology Research, Inc. | Lafayette, Indiana, United States | — |
| Maryland Hematology & Oncology. P.A. | Silver Spring, Maryland, United States | — |
| Henry Ford Health System | Detroit, Michigan, United States | — |
| Metro-Minnesota Community Oncology Research Consortium | Saint Louis Park, Minnesota, United States | — |
+ 102 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04589845